Miacalcic (Calcitonin Salmon, Synthetic)

Calcitonin salmon binds to specific calcitonin receptors on osteoclasts, suppressing their bone‑resorbing activity. This reduces calcium release from bone and promotes renal calcium excretion, leading to lower serum calcium concentrations and improved bone stability.

The dose of Miacalcic is determined by the prescribing clinician based on the patient’s condition, severity, and response. Dosage regimens are individualised and should follow the prescriber’s instructions and local clinical guidelines.

Safety of calcitonin salmon in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by the treating physician.

To order Miacalcic, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

The primary alternative class is bisphosphonates, which also inhibit bone resorption but act through different cellular pathways. Calcitonin provides a rapid, short‑term reduction in serum calcium and is useful when a quick response is needed, whereas bisphosphonates have a longer‑lasting effect on bone density.

Miacalcic must be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use and avoid exposing it to temperatures outside the recommended range.

Miacalcic is supplied as an injectable solution and can be given by intramuscular, intravenous, or subcutaneous injection. The route, site and frequency are selected by the prescriber according to the therapeutic indication and patient needs.

Serious adverse events include severe allergic reactions such as anaphylaxis, marked hypocalcemia that can cause neuromuscular symptoms, hypotension, and injection‑site infections. Patients should be monitored closely for these signs, and treatment should be stopped immediately if they occur.

Miacalcic is contraindicated in individuals with known hypersensitivity to calcitonin salmon or any excipients in the formulation. Caution is also advised for patients with severe renal impairment or those who have experienced severe hypocalcemia previously.